ViraCor-IBT Laboratories launches a comprehensive influenza and respiratory virus testing service that will assist physicians in detecting a range of respiratory viruses, including 2009 Influenza A H1N1 as well as other influenza subtypes and common respiratory viruses, such as rhinovirus, respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). The ViraCor-IBT testing service will assist physicians in rapidly identifying the cause of an infection.
"Correctly diagnosing a respiratory viral infection from a patient's symptoms alone is very difficult because most respiratory viruses cause very similar symptoms," says Steve Kleiboeker, PhD, chief scientific officer for the combined ViraCor-IBT Laboratories. "The only way to be certain which pathogen is causing the infection is to run a laboratory test. With the emergence of antiviral-resistant viruses and new pathogens such as the pandemic Influenza A H1N1, testing for respiratory viruses has never been more important."
The suite of tests available as part of the ViraCor-IBT influenza and respiratory virus testing service includes:
- the xTAG Respiratory Viral Panel (RVP),
- a test to detect 2009 Influenza A H1N1,
- a test to detect and distinguish between Influenza A H1 and Influenza A H3 subtypes and
- a test that identifies drug resistant mutations of 2009 Influenza A H1N1.
xTAG RVP simultaneously detects 12 viral targets with one patient sample. The test detects major respiratory viruses including RSV A and B, Influenza A and B, parainfluenza types 1, 2 and 3, human metapneumovirus, rhinovirus and adenovirus.
The ViraCor-IBT 2009 test will assist doctors in determining if a patient is carrying the Influenza A H1N1 virus. The test first identifies presence of and infection by 2009 Influenza A H1N1. It was validated by public health laboratories with samples confirmed to contain 2009 Influenza A H1N1.
ViraCor-IBT's Influenza A H1 and H3 subtyping test assists in distinguishing between the two most common seasonal Influenza A subtypes so the correct antiviral can be prescribed to a patient.
The 2009 Influenza A H1N1 Antiviral Resistance test is designed to detect mutations of the Influenza strain that are resistant to oseltamivir (Tamiflu®). The CDC recently reported cases of immunocompromised patients who were carrying oseltamivir-resistant mutations.
The new testing service offers physicians and laboratories several ordering options, including reflex testing, which allows ViraCor-IBT to perform a needed second test without having to re-contact the ordering physician.
"ViraCor-IBT is committed to providing hospitals and physicians the most advanced testing options along with the fastest turnaround time of patient results in the industry," says John Martin, president of the combined ViraCor-IBT Laboratories. "As we head into an unpredictable flu season, we are pleased to offer not only a high quality molecular H1N1 test, but three additional assays that will give our clients the tools and information they need to help diagnose and treat influenza and other respiratory illnesses and provide the best possible patient care."
All of ViraCor-IBT's respiratory virus testing options will be available as of September 1, with the exception of the 2009 Influenza A H1N1 Antiviral Resistance test, which will be available later in the month